GH Research Remains Undervalued Ahead Of Pivotal Phase III ProgramSeeking Alpha · 2 days ago
GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of “Moderate Buy” from AnalystsDefense World · Oct 3, 2026
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion OpportunitiesSeeking Alpha · Sep 20, 2026
GH Research Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Aug 6, 2026GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.29 | -$0.23 | Beat |
| May 14, 2026 | -$0.27 | -$0.31 | Miss |
| Mar 5, 2026 | -$0.29 | -$0.23 | Beat |
| Nov 6, 2025 | -$0.23 | -$0.23 | Beat |
| Aug 7, 2025 | -$0.22 | -$0.15 | Beat |
| May 8, 2025 | -$0.61 | -$0.19 | Beat |